The Conversation (0)
- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Revive Therapeutics: Repurposing Drugs for Inflammation and Infectious Diseases
Apr. 14, 2020 01:37PM PST
Life Science Investing News
Revive Therapeutics (CSE:RVV) has launched its campaign on the Investing News Network’s life sciences channel.
Revive Therapeutics (CSE:RVV) has launched its campaign on the Investing News Network’s life sciences channel.
Revive Therapeutics is a life sciences company working to develop treatments for rare disorders and infectious diseases. The company is focused on developing IP and treatments for infectious diseases while also leveraging compounds like psilocybin to develop new treatments and therapies. Revive Therapeutics is also developing a portfolio of cannabis-based IP with a focus on autoimmune hepatitis and ischemia.
Revive Therapeutics recently announced it was exploring the use of the drug bucillamine as a potential novel treatment for infectious diseases including influenza and the side effects of the coronavirus disease (COVID-19). The company has applied for a provisional patent with the US Patent and Trademark Office entitled “Use of Bucillamine in the Treatment of Infectious Diseases”.
Revive Therapeutics’ company highlights include the following:
- Secured a patent relating to the use of bucillamine in the treatment of gout
- Applied for a provisional patent with the U.S. Patent and Trademark Office entitled “Use of Bucillamine in the Treatment of Infectious Diseases”
- Owns a portfolio of four patents regarding cannabinoid delivery systems, including one specific to the treatment of autoimmune hepatitis
- Received orphan drug status from the US FDA for CBD in the treatment of autoimmune hepatitis
- Received orphan drug status from the US FDA for bucillamine in the treatment of cystinuria
- Acquired Psilocin Pharma Corp, a drug development company specializing in the development of psilocybin-based formulations
- Developing psilocybin-based compounds currently in the preclinical stage leveraging unique delivery mechanisms
- Filed provisional patent applications for novel psilocybin delivery systems including tablets, oral compositions, hard-shell capsules, gumdrops, oral strips and sublingual and buccal administration.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.